Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vandefitemcel - SanBio

Next Previous
Drug Profile

Vandefitemcel - SanBio

Alternative Names: AKUUGO; Modified bone marrow derived mesenchymal stem cells - SanBio; SB-623

Latest Information Update: 14 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SanBio
  • Developer SanBio; Sumitomo Pharma; Sumitomo Pharma America
  • Class Antidementias; Antiparkinsonians; Mesenchymal stem cell therapies; Neural stem cell therapies; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Traumatic brain injuries
  • Phase II Cerebral infarction; Stroke
  • Preclinical Dry age-related macular degeneration; Parkinson's disease; Retinitis pigmentosa; Spinal cord injuries
  • Research Alzheimer's disease

Most Recent Events

  • 12 Feb 2025 Adverse events and efficacy data from the phase-II STEMTRA trial in Traumatic brain injuries released by SanBio
  • 31 Jul 2024 Registered for Traumatic brain injuries in Japan (Intracerebral)
  • 01 Mar 2024 Vandefitemcel is still in research for Alzheimer's-disease in USA (SanBio Pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top